Unique ID issued by UMIN | UMIN000034410 |
---|---|
Receipt number | R000039240 |
Scientific Title | A phase 2 study of induction chemotherapy followed by chemoradiotherapy for patients with borderline resectable pancreatic cancer |
Date of disclosure of the study information | 2018/10/10 |
Last modified on | 2019/04/10 17:20:10 |
A phase 2 study of induction chemotherapy followed by chemoradiotherapy for patients with borderline resectable pancreatic cancer
A phase 2 study of induction chemotherapy followed by chemoradiotherapy for patients with borderline resectable pancreatic cancer
A phase 2 study of induction chemotherapy followed by chemoradiotherapy for patients with borderline resectable pancreatic cancer
A phase 2 study of induction chemotherapy followed by chemoradiotherapy for patients with borderline resectable pancreatic cancer
Japan |
Pancreatic cancer
Hepato-biliary-pancreatic surgery |
Malignancy
NO
To investigate that the efficacy of the induction chemotherapy followed by chemoradiotherapy for borderline resectable pancreatic cancer
Efficacy
R0 resection rate
Relapse-free survival
Overall survival
Treatment completion rate
Adverse effect
Pathological response
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
A total of three courses of nab-Paclitaxel and Gemcitabine followed by TS-1 with concurrent radiotherapy of 45Gy for 5 weeks
20 | years-old | <= |
85 | years-old | >= |
Male and Female
1) Histologically proven or radiologically confirmed pancreatic cancer
2) No prior treatment for pancreatic cancer
3) Age between 20 to 85
4) ECOG performance status 0/1
5) White blood cell count above 3000/mm3
Neutrophil count above 1000/mm3
Platelet count above 100000/mm3
Hemoglobin above 8.0 g/dl
Total billirubin below 3.0 mg/dl
AST, ALT below 150 IU/L
Creatinine below 1.5 mg/dl
6) No exclusion criteria
7) Proper informed consent
1) Contraindication of nab-PTX, GEM, TS-1
2) Pleuritic effusion refractory to diuretics
3) Presence of distant metastasis
4) Presence of concurrent advanced cancer
5) Presence of clinically obvious infection
6) Prior radiotherapy to abdominal lesions
7) Previous history of myocardial infarction within three months
8) Severely mental retardation
9) Current status of pregnancy and lactation, or the possibility of these statuses.
40
1st name | Minoru |
Middle name | |
Last name | Kitago |
Keio University School of Medicine
Department of Surgery
1608582
Shinanomachi 35, Shinjuku, Tokyo
03-3353-1211
dragonpegasus@keio.jp
1st name | Minoru |
Middle name | |
Last name | Kitago |
Keio University School of Medicine
Department of Surgery
1608582
Shinanomachi 35 Shijuku Tokyo
0333531211
dragonpegasus@keio.jp
Keio University School of Medicine
Keio University School of Medicine
Self funding
Department of Surgery, Tochigi Medical Center
Department of Surgery, Ichikawa General Hospital, Tokyo Dental College
Department of Surgery, Tokyo Medical Center
Department of Surgery, Saitama National Hospital
Department of Surgery, Hiratsuka City Hospital
Department of Surgery, Fussa Hospital
Ethical committee, Keio University
Shinanomachi 35, Shinjuku, Tokyo
03-3353-1211
med-rinri-jimu@adst.keio.ac.jp
NO
独立行政法人 国立病院機構 栃木医療センター 外科 (栃木)
東京歯科大学市川総合病院 外科 (千葉)
独立行政法人国立病院機構東京医療センター 外科 (東京)
独立行政法人 国立病院機構 埼玉病院 外科 (埼玉)
平塚市民病院 外科 (神奈川)
公立福生病院 外科 (東京)
2018 | Year | 10 | Month | 10 | Day |
Unpublished
Enrolling by invitation
2018 | Year | 10 | Month | 09 | Day |
2019 | Year | 03 | Month | 25 | Day |
2019 | Year | 03 | Month | 25 | Day |
2023 | Year | 12 | Month | 31 | Day |
2018 | Year | 10 | Month | 09 | Day |
2019 | Year | 04 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039240